Fulcrum Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Fulcrum Therapeutics

01/05/2025 14:32

Fulcrum Therapeutics Inc FULC.OQ reported a quarterly adjusted loss of 28 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -43 cents.  The mean expectation of five analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -35 cents to -23 cents per share.

Reported revenue was zero​; analysts expected zero.

Fulcrum Therapeutics Inc's reported EPS for the quarter was a loss of 28 cents​.

The company reported a quarterly loss of $17.66 million.

Fulcrum Therapeutics Inc shares had risen by 33.7% this quarter and lost 18.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 19.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $4.00

This summary was machine generated from LSEG data May 1 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.29
-0.28
Beat
Dec. 31 2024
-0.32
-0.31
Beat
Sep. 30 2024
-0.41
-0.35
Beat
Jun. 30 2024
-0.01
0.87
Beat